Overview
DocGo Q3 2025 revenue beats analyst expectations despite a 49% yr/yr decline
Adjusted EBITDA loss for Q3 2025 beats analyst estimates
Net loss in Q3 2025 due to $16.7 mln non-cash impairments
Company achieves record volumes across all major business lines
Outlook
DocGo expects full-year 2025 revenue of $315-$320 mln
Company anticipates full-year 2026 revenue of $280-$300 mln
DocGo forecasts full-year 2025 adjusted EBITDA loss of $25-$28 mln
Company projects full-year 2026 adjusted EBITDA loss of $15-$25 mln
Result Drivers
MIGRANT PROGRAM WIND-DOWN - Revenue decline attributed to wind-down of migrant-related programs, impacting overall results
CORE BUSINESS GROWTH - Excluding migrant-related programs, revenue increased 8% in core business lines
RECORD VOLUMES - Achieved record volumes across all major business lines, with notable increases in care gap closure and transitions of care
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $70.81 mln | $70 mln (7 Analysts) |
Q3 EPS | -$0.28 | ||
Q3 Net Income | -$29.70 mln | ||
Q3 Adjusted EBITDA | Beat | -$7.20 mln | -$8.62 mln (7 Analysts) |
Q3 Gross Margin | 20.00% |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy"
Wall Street's median 12-month price target for DocGo Inc is $3.00, about 63% above its November 7 closing price of $1.11
Press Release: ID:nBw5XRJhja
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)